Photo of Scott G. Franzblau

Scott G. Franzblau


Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences

Email:

sgf@uic.edu

Related Sites:

About

Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites

Teaching and Supervision

Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016
Fund of Drug Action III (PHAR 333), 8/24/2015 – 12/4/2015
Fund of Drug Action III (PHAR 333), 8/24/2015 – 12/4/2015
Fund of Drug Action III (PHAR 333), 8/25/2014 – 12/5/2014
Fund of Drug Action III (PHAR 333), 8/25/2014 – 12/5/2014

Selected Grants

Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980

NDA Anti-tuberculosis against Teixobactin, NovoBiotic Pharmaceuticals LLC., 7/5/2021 - 7/4/2022, No Obligated Amount Set; No Anticipated Amount Set

Anti-tubercular studies on Jyothishmathi Institute Compounds, Jyothishmathi Institute of Pharmaceutical Sciences., 3/23/2021 - 3/22/2026, No Obligated Amount Set; No Anticipated Amount Set

In vitro Evaluation of Small Molecule Compounds in USAMRIID�s Core Antibiotic Screening Program, US Army., 3/4/2021 - 3/3/2024, No Obligated Amount Set; No Anticipated Amount Set

MTA: Anti-tubercular studies against Teixobactin, NovoBiotic Pharmaceuticals LLC., 1/1/2021 - 12/31/2026, No Obligated Amount Set; No Anticipated Amount Set

Incoming MTA - Anti-tubercular studies on UNAM Compounds, Universidad Nacional Autonoma de Mexico., 1/1/2021 - 12/31/2026, No Obligated Amount Set; No Anticipated Amount Set

Global TB Strains, University of California - San Francisco., 1/1/2021 - 12/31/2026, No Obligated Amount Set; No Anticipated Amount Set

Anti-tubercular studies on Wheaton College Small-molecule organic compounds � peptoids, Wheaton College., 11/15/2020 - 11/14/2022, No Obligated Amount Set; No Anticipated Amount Set

★ “Targeting Protein Degradation ClpC1 ATPase”, National Institutes of Health., 1/4/2019 - 3/31/2024, Obligated Amount: $3834174; No Anticipated Amount Set

Selected Publications

Park, CR, Paik, S, Kim, YJ, Kim, JK, Jeon, SM, Lee, SH, Whang, J, Cheng, J, Suh, JW, Cao, J, Shetye, G, Chen, SN, McAlpine, J, Pauli, GF, Franzblau, S, Cho, S, Jo, EK. (2021). Rufomycin Exhibits Dual Effects Against Mycobacterium abscessus Infection by Inducing Host Defense and Antimicrobial Activities. Frontiers in Microbiology, 12. doi:10.3389/fmicb.2021.695024.

Shetye, GS, Choi, KB, Kim, CY, Franzblau, SG, Cho, S. (2021). In vitro profiling of antitubercular compounds by rapid, efficient, and nondestructive assays using autoluminescent mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 65, (8). doi:10.1128/AAC.00282-21.

Nandikolla, A, Srinivasarao, S, Khetmalis, YM, Kumar, BK, Murugesan, S, Shetye, G, Ma, R, Franzblau, SG, Sekhar, KVGC. (2021). Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis. Toxicology in Vitro, 74. doi:10.1016/j.tiv.2021.105137.

Ganesan, MS, Raja, KK, Murugesan, S, Karankumar, B, Faheem, F, Thirunavukkarasu, S, Shetye, G, Ma, R, Franzblau, SG, Wan, B, Rajagopal, G. (2021). Quinoline-Proline, Triazole Hybrids: Design, Synthesis, Antituberculosis, Molecular Docking, and ADMET Studies. Journal of Heterocyclic Chemistry, 58, (4), 952-968. doi:10.1002/jhet.4229.

Thompson, AM, O’Connor, PD, Yardley, V, Maes, L, Launay, D, Braillard, S, Chatelain, E, Wan, B, Franzblau, SG, Ma, Z, Cooper, CB, Denny, WA. (2021). Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters, 12, (2), 275-281. doi:10.1021/acsmedchemlett.0c00649.

Liu, R, Markley, L, Miller, PA, Franzblau, S, Shetye, G, Ma, R, Savková, K, Mikušová, K, Lee, BS, Pethe, K, Moraski, GC, Miller, MJ. (2021). Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds. RSC Medicinal Chemistry, 12, (1), 62-72. doi:10.1039/d0md00390e.

Thompson, AM, O’Connor, PD, Marshall, AJ, Yardley, V, Maes, L, Gupta, S, Launay, D, Braillard, S, Chatelain, E, Wan, B, Franzblau, SG, Ma, Z, Cooper, CB, Denny, WA. (2021). Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. European Journal of Medicinal Chemistry, 209. doi:10.1016/j.ejmech.2020.112914.

Velappan, AB, Kesamsetty, D, Datta, D, Ma, R, Hari, N, Franzblau, SG, Debnath, J. (2020). 1,3-Oxazine-2-one derived dual-targeted molecules against replicating and non-replicating forms of Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 208. doi:10.1016/j.ejmech.2020.112835.

Lu, GL, Tong, AST, Conole, D, Sutherland, HS, Choi, PJ, Franzblau, SG, Upton, AM, Lotlikar, MU, Cooper, CB, Denny, WA, Palmer, BD. (2020). Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry, 28, (22). doi:10.1016/j.bmc.2020.115784.

Education

Degrees:
B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982

Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984

Selected Presentations

Wolf, Nina M, Lee, Hyun, Nam, Joowon, Hong, Jeongpyo, Duc, Nguyen Minh, Ho, Ngo Anh, Lee, Hanki, Suh, Joo-Won, Pauli, Guido F, Franzblau, Scott G, Cho, Sanghyun, Abad-Zapatero, Celerino. (2019 July 20). Structures of ClpC1-NTD with potent anti-TB cyclic peptides Rufomycin and Ecumicin: implications for the mechanism of action and design of therapeutic agents. doi:10.1107/s0108767319099409.